Олигометастатический рак предстательной железы: локальное лечение и метастазнаправленная терапия
https://doi.org/10.17650/1726-9776-2024-20-1-146-152
Аннотация
Статья посвящена современным методам диагностики и лечения олигометастатического рака предстательной железы на основании анализа большого количества данных литературы. Основная цель метастазнаправленной терапии при олигометастатическом раке предстательной железы – замедление прогрессирования метастатического процесса, увеличение времени до начала паллиативной андрогендепривационной терапии и излечение пациента. В настоящее время недостаточно высококачественных данных о лечении и эффективности метастазнаправленной терапии. Необходимо стандартизировать терминологию, использовать весь потенциал визуализации позитронно-эмиссионной томографии, совмещенной с компьютерной томографией, с простатическим специфическим мембранным антигеном, комбинировать ее с молекулярно-генетическими исследованиями и стратифицировать факторы риска для каждого пациента в отдельности.
Об авторах
М. Д. Тер-Ованесов
ЧУЗ «Центральная клиническая больница «РЖД-Медицина»; ФГБОУ ВО «Российский университет медицины» Минздрава России
Россия
Конфликт интересов:
Россия
129128 Москва, ул. Будайская, 2; 127473 Москва, ул. Делегатская, 20, стр. 1
Конфликт интересов:
Нет
Д. М. Ягудаев
ЧУЗ «Центральная клиническая больница «РЖД-Медицина»; ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы»
Россия
Конфликт интересов:
Россия
Ягудаев Даниэль Меерович - доктор медицинских наук, профессор кафедры эндоскопической урологии и ультразвуковой диагностики ФНМО МИ «РУДН»; заведующий отделением онкоурологии ЧУЗ «ЦКБ «РЖД-Медицина».
129128 Москва, ул. Будайская, 2; 117198 Москва, ул. Миклухо-Маклая, 6
Конфликт интересов:
Нет
Е. В. Аниканова
ЧУЗ «Центральная клиническая больница «РЖД-Медицина»; ФГБОУ ВО «Российский университет медицины» Минздрава России
Россия
Конфликт интересов:
Россия
129128 Москва, ул. Будайская, 2; 127473 Москва, ул. Делегатская, 20, стр. 1
Конфликт интересов:
Нет
К. И. Медведев
ФГБОУ ВО «Российский университет медицины» Минздрава России
Россия
Конфликт интересов:
Россия
127473 Москва, ул. Делегатская, 20, стр. 1
Конфликт интересов:
Нет
Список литературы
1. Malignant tumors in Russia in 2021 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 252 p. (In Russ.).
2. Desai M.M., Cacciamani G.E., Gill K. et al. Trends in Incidence of Metastatic Prostate Cancer in the US. JAMA Netw Open 2022;5(3):e222246. DOI: 10.1001/jamanetworkopen.2022.2246
3. SEER Cancer Stat Facts: Prostate Cancer. Bethesda, MD: National Cancer Institute. Available at: https://seer.cancer.gov/statfacts/html/prost.html.
4. Zhu Y., Mo M., Wei Y. et al. Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol 2021;18(5):282–301. DOI: 10.1038/s41585-021-00442-8
5. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (Erratum in: CA Cancer J Clin 2020;70(4):313). CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492
6. Popov S.V., Guseynov R.G., Khizha V.V. et al. Prostate cancer: сurrent situation in Russia and Saint Petersburg according to medical statistical indicators. Onkourologiya = Cancer Urology 2023;19(1): 102–14. (In Russ.). DOI: 10.17650/1726-9776-2023-19-1-102-114
7. Hellman S., Weichselbaum R.R. Oligometastases. J Clin Oncol 1995;13(1):8–10. DOI: 10.1200/JCO.1995.13.1.8
8. Uppal A., Ferguson M.K., Posner M.C. et al. Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis 2014;31(6):735–48. DOI: 10.1007/s10585-014-9664-3
9. Reyes D.K., Pienta K.J. The biology and treatment of oligometastatic cancer. Oncotarget 2015;6(11):8491–524. DOI: 10.18632/oncotarget.3455
10. Guckenberger M., Lievens Y., Bouma A.B. et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 2020;21(1):e18–28. DOI: 10.1016/S1470-2045(19)30718-1
11. Mottet N., Cornford P., van den Bergh R.C.N. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. 2022. Ppresented at the EAU Annual Congress Amsterdam 2022. EAU Guidelines Office, Arnhem, The Netherlands. Available at: http://uroweb.org/guidelines/compilations-of-all-guidelines/ (accessed September 30, 2022).
12. Maurer T., Eiber M., Schwaiger M., Gschwend J.E. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 2016;13(4):226–35. DOI: 10.1038/nrurol.2016.26
13. Hofman M.S., Lawrentschuk N., Francis R.J. et al. proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curativeintent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020;395(10231):1208–16. DOI: 10.1016/S0140-6736(20)30314-7
14. Perera M., Papa N., Roberts M. et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 2020;77(4):403–17. DOI: 10.1016/j.eururo.2019.01.049
15. Zaorsky N.G., Calais J., Fanti S. et al. Salvage therapy for prostate cancer after radical prostatectomy. Nat Rev Urol 2021;18(11):643–68. DOI: 10.1038/s41585-021-00497-7
16. Grubmüller B., Baltzer P., Hartenbach S. et al. PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact. Clin Cancer Res 2018;24(24):6300–7. DOI: 10.1158/1078-0432.CCR-18-0768
17. Morris M.J., Rowe S.P., Gorin M.A. et al. CONDOR Study Group. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res 2021;27(13):3674–82. DOI: 10.1158/1078-0432.CCR-20-4573
18. Fendler W.P., Calais J., Eiber M. et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 2019;5(6):856–63. DOI: 10.1001/jamaoncol.2019.0096
19. Hope T.A., Eiber M., Armstrong W.R. et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol 2021;7(11):1635–42. DOI: 10.1001/jamaoncol.2021.3771
20. Katipally R.R., Pitroda S.P., Juloori A. et al. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol 2022;19(9):585–99. DOI: 10.1038/s41571-022-00655-9
21. Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23):1655–9. DOI: 10.1056/NEJMoa003013
22. Bristow R.E., Tomacruz R.S., Armstrong D.K. et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20(5):1248–59. DOI: 10.1200/JCO.2002.20.5.1248
23. Psaila B., Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009;9:285–93. DOI: 10.1038/nrc2621
24. Kang J., La Manna F., Bonollo F. et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett 2022;530:156–69. DOI: 10.1016/j.canlet.2022.01.015
25. Furesi G., Rauner M., Hofbauer L.C. Emerging Players in prostate cancer-bone niche communication. Trends Cancer 2021;7(2):112–21. DOI: 10.1016/j.trecan.2020.09.006
26. Kim M.Y., Oskarsson T., Acharyya S. et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139(7):1315–26. DOI: 10.1016/j.cell.2009.11.025
27. Tzelepi V., Efstathiou E., Wen S. et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 2011;29(18):2574–81. DOI: 10.1200/JCO.2010.33.2999
28. Connor M.J., Shah T.T., Horan G. et al. Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol 2020;17(3):168–82. DOI: 10.1038/s41571-019-0284-3
29. Kadmon D., Heston W.D., Fair W.R. Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol 1982;127(6):1238–42. DOI: 10.1016/s0022-5347(17)54306-2
30. Linxweiler J., Hajili T., Zeuschner P. et al. Primary tumor resection decelerates disease progression in an orthotopic mouse model of metastatic prostate cancer. Cancers (Basel) 2022;14(3):737. DOI: 10.3390/cancers14030737
31. Dai B., Zhang S., Wan F.N. et al. Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial. Eur Urol Oncol 2022;5(5):519–25. DOI: 10.1016/j.euo.2022.06.001
32. Chung D.Y., Kang D.H., Jung H.D. et al. Cytoreductive prostatectomy may improve oncological outcomes in patients with oligometastatic prostate cancer: an updated systematic review and meta-analysis. Investig Clin Urol 2023;64(3):242–54. DOI: 10.4111/icu.20230058
33. Mao Y., Hu M., Yang G. et al. Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis. World J Surg Oncol 2022;20(1):255. DOI: 10.1186/s12957-022-02715-x
34. Kim I.Y., Mitrofanova A., Panja S. et al. Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. Prostate Int 2022;10(2):75–9. DOI: 10.1016/j.prnil.2022.03.001
35. Parker C.C., James N.D., Brawley C.D. et al. Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392(10162):2353–66. DOI: 10.1016/S0140-6736(18)32486-3
36. Boevé L.M.S., Hulshof M.C.C.M., Vis A.N. et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 2019;75(3):410–8. DOI: 10.1016/j.eururo.2018.09.008
37. Burdett S., Boevé L.M., Ingleby F.C. et al. STOPCAP M1 Radiotherapy Collaborators. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol 2019;76(1):115–24. DOI: 10.1016/j.eururo.2019.02.003
38. Phillips R., Shi W.Y., Deek M. et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 2020;6(5):650–9. DOI: 10.1001/jamaoncol.2020.0147
39. Ost P., Reynders D., Decaestecker K. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018;36(5):446–53. DOI: 10.1200/JCO.2017.75.4853
40. Ost P., Bossi A., Decaestecker K. et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 2015;67(5):852–63. DOI: 10.1016/j.eururo.2014.09.004
41. Ploussard G., Gandaglia G., Borgmann H. et al. EAU-YAU Prostate Cancer Working Group. Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review. Eur Urol 2019;76(4):493–504. DOI: 10.1016/j.eururo.2018.10.041
42. Bravi C.A., Fossati N., Gandaglia G. et al. Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought. Eur Urol 2020;78(5):661–9. DOI: 10.1016/j.eururo.2020.06.043
43. Steuber T., Jilg C., Tennstedt P. et al. Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. Eur Urol Focus 2019;5(6):1007–13. DOI: 10.1016/j.euf.2018.02.015
44. Deek M.P., van der Eecken K., Sutera P. et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol 2022;40(29):3377–82. DOI: 10.1200/JCO.22.00644
45. Colosini A., Bernardi S., Foroni C. et al. Stratification of oligo-metastatic prostate cancer patients by liquid biopsy: clinical insights from a pilot study. Biomedicines 2022;10(6):1321. DOI: 10.3390/biomedicines10061321
46. Greco C., Pares O., Pimentel N. et al. Phenotype-oriented ablation of oligometastatic cancer with single dose radiation therapy. Int J Radiat Oncol Biol Phys 2019;104(3):593–603. DOI: 10.1016/j.ijrobp.2019.02.033
Рецензия
Для цитирования:
Тер-Ованесов М.Д., Ягудаев Д.М., Аниканова Е.В., Медведев К.И. Олигометастатический рак предстательной железы: локальное лечение и метастазнаправленная терапия. Онкоурология. 2024;20(1):146-152. https://doi.org/10.17650/1726-9776-2024-20-1-146-152
For citation:
Ter-Ovanesov M.D., Yagudaev D.M., Anikanova E.V., Medvedev K.I. Oligometastatic prostate cancer: local treatment and metastasis-directed therapy. Cancer Urology. 2024;20(1):146-152. (In Russ.) https://doi.org/10.17650/1726-9776-2024-20-1-146-152
Просмотров:
345
Послать статью по эл. почте 
